Skip Navigation

Osama Rahma, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Physician
  • Medical Oncologist, Center for Immuno-Oncology
  • Medical Oncologist, Gastrointestinal Oncology
  • Assistant Professor of Medicine, Harvard Medical School

Contact Information

  • Appointments617-632-2070
  • Office Phone Number617-632-2563 (Center for Immuno-Oncology)
    617-632-5929 (Gastrointestinal Oncology)
  • Fax617-582-7227

Bio

Dr. Rahma received his medical degree from University of Damascus in 1998. He completed his residency in Internal Medicine at East Carolina University followed by Geriatrics Fellowship at University of Hawaii. Dr. Rahma joined the National Cancer Institute (NCI) as an Immunotherapy Research Fellow in the Vaccine Branch in 2009 and completed a Fellowship in Medical Oncology in 2013 specializing in Cancer Immunotherapy and Gastrointestinal (GI) Oncology. Prior to joining Dana-Farber Cancer Institute, Dr. Rahma was the co-leader of the Hepatobiliary and Pancreatic Cancer Program at University of Virginia where he led translational research efforts as the Principal Investigator of many clinical trials.

Dr. Rahma is currently a Principal Investigator at the Center for Immuno-Oncology and Gastroenterology Cancer Center at Dana-Farber Cancer Institute. His research focus is on drug development of combinational immune therapeutics with the goal of moving immunotherapy to GI cancers and understanding the resistance mechanism to immunotherapy in GI cancers. He is currently the national lead of many studies combining immune checkpoint inhibitors and standard of care including chemotherapy and radiation therapy in addition to many novel combinations. Dr. Rahma also leads the Immune Toxicity Work Group at Dana-Farber, a unique program that is devoted to mitigating immune related toxicities.

Board Certification:

  • Internal Medicine, 2004
  • Medical Oncology, 2013

Fellowship:

  • National Cancer Institute, National Institutes of Health, Hematology/Medical Oncology

Residency:

  • East Carolina University, Internal Medicine

Medical School:

  • Damascus University

Recent Awards:

  • Oncology Trainee Award, The Conquer Cancer Foundation of ASCO 2012
  • Danny Danielson Translational Innovation Award, Hoosier Cancer Research Network 2015

Research

Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med. 2010 Jan 28;8:8. PMID: 20109232. PMCID: PMC2843651

2010

Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother. 2012 Mar;61(3):373-84. PMID: 21927947. PMCID: PMC3708463

2012

Rahma OE, A. Duffy, D. J. Liewehr, S. M. Steinberg and T. F. Greten. Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials. Ann Oncol. 2013 Aug;24(8):1972-9. PMID: 23670093. PMCID: PMC3718508

2013

Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM and Khleif SN. The immunological and clinical effects of mutated Ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55. PMID:24565030. PMCID: PMC3942063

2014

Rahma OE, Gammoh E, Simon R, Khleif SN. Is the "3+3" dose escalation phase 1 clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res. 2014 Sep 15;20(18):4758-67. PMID:25037736. PMCID:PMC4167476

2014

Ulahannan SV1, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. 2014 Nov;60(5):1637-44. PMID: 24996116. PMCID: PMC4211986

2014

Rahma OE, Herrin VE, Ibrahim RA, Toubaji A, Bernstein S, Dakhee O, Steinberg SM, Abu Eid R, Mkrtichyan M, Berzofsky JA and Khleif SN. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. J Transl Med. 2014 Dec 16;12:353. PMID: 25510844. PMCID: PMC4269078

2014

Ulahannan SV*, Rahma OE*, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma (BTC): a review of chemotherapy trials in the past two decades. Hepat Oncol. 2015 Jan; 2(1):39-50. PMID: 25685318. PMCID: PMC4326054. *Shared first-authorship

2015

Lynch AC, Sen JM, Ward LP, DeGregory KA, Kunk PR, Wages NA, Ramsdale EE, Rahma OE. Real-world evaluation of hematologic toxicity associated with nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Am J Cancer Res. 2015 Sept; 2 (1):26-36. doi:10.7726/ajcrco.2015.1002

2015

Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF. A Phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on Sorafenib. United European Gastroenterol J. 2015 Oct;3(5):453-61. PMID: 26535124. PMCID: PMC4625750

2015

Newhook TE, Lindberg JM, Adair SJ, Kim AJ, Stelow EB, Rahma OE, Parsons JT, Bauer TW. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Ann Surg Oncol. 2016 Jun;23(6):1993-2000. DOI: 10.1245/s10434-016-5116-4. PMID: 26847682

2016

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750 – an antisense oligonucleotide against eIF4E – in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. Int J Cancer. 2016 May 19. doi: 10.1002/ijc.30199. PMID: 27194579

2016

Song JY, Eberle FC, Xi L, Raffeld M, Rahma OE, Wilson WH, Dunleavy K, Pittaluga S, Jaffe E. Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma. Am J Surg Pathol. 2011 May;35(5):767-72. PMID: 21490448. PMCID: PMC3077769

2011

Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y). 2011 Aug;7(8):517-64. PMID: 22298988. PMCID: PMC3264936

2011

Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies and future directions. Front Oncol. 2012 May 24;2:52. PMID: 22655277. PMCID: PMC3359480

2012

Rahma OE, Burotto M, Do Canto LM, Germanos AA, Haddad BR, Marshall JL. Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence. World J Gastrointest Oncol. 2013 Nov 15; 5(11): 198–203. PMID: 24244806. PMCID: PMC3828635

2013

Gaertner KM, Caldwell SH, Rahma OE. A case of retinal tear associated with use of sorafenib.  Front. Oncol. 2014 Jul 24;4:196. PMID: 25105094. PMCID: PMC4109517

2014

Zakharia Y, Rahma OE, Khleif SN. Ovarian cancer from an immune perspective. Radiat Res. 2014 Aug;182(2):239-51. PMID: 25036981

2014

Rahma OE, Zaw Myint ZW, Estfan. Dendritic cell cancer vaccines for treatment of colon cancer. Current Colorectal Cancer Reports. 2014 Dec;10(4):470-476.  DOI 10.1007/s11888-014-0243-4

2014

Emaculate Verla-Tebit, Rahma OE. Regression of hepatocellular carcinoma after treatment of hepatitis C- a case report. J Gastrointest Oncol. 2015 Jun;6(3):E52-4. PMID: 26029467. PMCID: PMC4397252   

2015

Berbari1 B, Romano AM, Bhatti R, Rahma OE. A case report of a poorly differentiated neuroendocrine carcinoma diagnosed in the bone marrow. Gastroenterology & Hepatology Open Access. 2015 Dec;3(2):00073. DOI: 10.15406/ghoa.2015.03.00073

2015

Kunk PR, Ramsdale EE, Rahma OE.  Targeting tumor angiogenesis in gastrointestinal malignancies. The Journal of Current Angiogenesis. 2015;4(2);1. DOI: 10.2174/2211552804666151116174614 http://www.eurekaselect.com/node/137007/article

2015

Carrera C, Kunk PR, Rahma OE. Small cell carcinoma of the gallbladder: Case report and comprehensive analysis of published cases. J Oncol. 2015 Dec;2015:304909. doi: 10.1155/2015/304909. . PMID: 26823665. PMCID: PMC4707370

2015

Kunk PR, Bauer TW, Slingluff CL, Rahma OE.  From bench to bedside: A comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016 Mar 15;4:14. PMID: 26981244. PMCID: PMC4791889

2016

Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL and Rahma OE. Beyond melanoma: targeting the PD-1/PD-L1 immune checkpoints in solid tumor malignancies. Immunotherapy. 2016 May;8(5):583-600. PMID: 27140411 

2016

Duffy A, Rahma OE, Greten TF. “Letter re: "Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group." Int J Cancer. 2013 Apr 1;132(7):1718. PMID: 22930464.

2013

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top